Skip to main content

Table 1 Phenotypic characterization of human AD-MSCs and HNDFs

From: Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential

 

AD-MSCs

HNDFs

 

% of positive cells (±SD)

% of positive cells (± SD)

Stem cell markers

  

Stro-1

3.7 ± 3.2

5.5 ± 0.4

CD146

1.5 ± 1.0

1.2 ± 1.2

CD133

0.4 ± 0.3

absent

CD34

absent

absent

CD117

0.1 ± 0.1

absent

ALDH

42 ± 8.3

41.0 ± 5.4

Mesenchymal markers

  

CD105

98.4 ± 1.0

95.6 ± 2.2

CD90

97.6 ± 2.5

94.1 ± 3.2

CD44

92.5 ±3.6

97.1 ± 1.1

CD29

95.5 ± 2.0

91.1 ± 5-4

AM markers

  

CD166

66.1 ± 26.4

80.4 ± 5.8

CD106

25.2 ± 15.1

35.6 ± 7.8

CD54

19.6 ± 9.4

25.7 ± 15.5

CD56

17.8 ± 12.2

39.6 ± 5.6*

CD49d

10.8 ± 3.4

58.9 ± 22.4**

Endothelial markers

  

CD31

absent

absent

vWf

absent

absent

Immunological markers

  

CD40

17,7 ± 5,9

84.1 ± 3.6**

CD80

4.6 ± 1.1

2.1 ± 0.9

CD86

2.6 ± 1.1

0.8 ± 0.7

CD45

absent

absent

HLA-II

0.5 ± 0.5

1.1 ± 1.2

HLA-I

93.3 ± 3.3

94.0 ± 2.8

  1. Table shows the phenotypic characterization of AD-MSCs and HNDFs in culture. FACS analysis was performed when all cultures were at 5 in vitro passages. Data represent the % of positive cells for each marker analyzed on AD-MSCs and on HNDF and are means ± SD. Variability of each marker tested among the different cell preparations were ≤ 10%. Note that some markers such as CD56, CD49d and CD40 are more highly expressed in HNDFs when compared to AD-MSCs. *p < 0.05 and **p < 0.01 compared to AD-MSCs.
Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us